260 related articles for article (PubMed ID: 35203733)
21. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
22. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
[TBL] [Abstract][Full Text] [Related]
23. β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar.
Sid Ahmed MA; Khan FA; Sultan AA; Söderquist B; Ibrahim EB; Jass J; Omrani AS
Antimicrob Resist Infect Control; 2020 Nov; 9(1):170. PubMed ID: 33131487
[TBL] [Abstract][Full Text] [Related]
24. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A
Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
[TBL] [Abstract][Full Text] [Related]
25. A 2.5-years within-patient evolution of a
Boulant T; Jousset AB; Bonnin RA; Barrail-Tran A; Borgel A; Oueslati S; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31636072
[TBL] [Abstract][Full Text] [Related]
26. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
27. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
28. Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.
Pincus NB; Rosas-Lemus M; Gatesy SWM; Bertucci HK; Brunzelle JS; Minasov G; Shuvalova LA; Lebrun-Corbin M; Satchell KJF; Ozer EA; Hauser AR; Bachta KER
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0098522. PubMed ID: 36129295
[TBL] [Abstract][Full Text] [Related]
29. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019.
Lee YL; Ko WC; Hsueh PR
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0200021. PubMed ID: 34807753
[TBL] [Abstract][Full Text] [Related]
30. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE
J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
[TBL] [Abstract][Full Text] [Related]
32. Ceftolozane-tazobactam- and ceftazidime-avibactam-resistant
Jacobs J; Maris A; Stratton C
Access Microbiol; 2020; 2(2):acmi000092. PubMed ID: 34568755
[No Abstract] [Full Text] [Related]
33. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
34. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G
J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505
[TBL] [Abstract][Full Text] [Related]
35. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
36. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21.
Karlowsky JA; Lob SH; Bauer KA; Esterly J; Siddiqui F; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad152. PubMed ID: 38222461
[TBL] [Abstract][Full Text] [Related]
37. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
Idowu T; Zhanel GG; Schweizer F
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
[TBL] [Abstract][Full Text] [Related]
38. Resistance to ceftazidime-avibactam and other new β-lactams in
Valzano F; La Bella G; Lopizzo T; Curci A; Lupo L; Morelli E; Mosca A; Marangi M; Melfitano R; Rollo T; De Nittis R; Arena F
Microbiol Spectr; 2024 Jun; ():e0426623. PubMed ID: 38934607
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
